Keros Therapeutics (NASDAQ:KROS) Trading Down 5.7% Following Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS)’s share price traded down 5.7% during trading on Tuesday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics traded as low as $18.12 and last traded at $18.32. 350,670 shares traded hands during trading, a decline of 24% from the average session volume of 463,453 shares. The stock had previously closed at $19.42.

Several other equities analysts also recently issued reports on KROS. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Scotiabank decreased their price target on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research note on Friday. Guggenheim cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday. HC Wainwright lowered their price target on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Wells Fargo & Company raised their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $81.33.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after buying an additional 46,041 shares in the last quarter. Barclays PLC lifted its position in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after buying an additional 35,022 shares in the last quarter. Wellington Management Group LLP bought a new position in Keros Therapeutics in the 3rd quarter worth approximately $868,000. Point72 DIFC Ltd raised its holdings in Keros Therapeutics by 9.8% during the 3rd quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock worth $1,118,000 after purchasing an additional 1,715 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after buying an additional 577,220 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

The firm has a market capitalization of $731.15 million, a price-to-earnings ratio of -3.48 and a beta of 1.20. The business has a 50 day moving average of $58.29 and a 200 day moving average of $52.50.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.33) EPS. As a group, equities analysts predict that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.